Brief: Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2
04/06/2025 12:16
Design Therapeutics Inc DSGN.O: DESIGN THERAPEUTICS ANNOUNCES START OF FRIEDREICH ATAXIA PATIENT DOSING EX-U.S. IN ITS RESTORE-FA PHASE 1/2 MULTIPLE-ASCENDING DOSE TRIAL OF DT-216P2 DESIGN THERAPEUTICS INC - FDA PLACES CLINICAL HOLD ON IND APPLICATION FOR U.S. SITES DESIGN THERAPEUTICS INC - NO ADVERSE EVENTS REPORTED IN DT-216P2 ADMINISTRATION DESIGN THERAPEUTICS INC - PHASE 1 SINGLE-ASCENDING DOSE TRIAL SHOWS DT-216P2 WELL-TOLERATED Source text: ID:nGNX9tmycD Further company coverage: DSGN.O
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1